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PURPOSE: Many of the currently used eradication regimens against Helicobacter pylori fail to cure the infection either due to
antimicrobial resistance or to poor patient compliance. The infection leads to increased risk of developing potentially severe
complications, such as gastric cancer. This study was aimed at assessing the efficacy and safety of a quadruple therapy with
furazolidone for H. pylori retreatment.
METHODS: Patients who had failed one or more eradication regimens against H. pylori infection underwent upper gastrointestinal
endoscopy. Biopsy specimens were taken from the gastric antrum and corpus for histology and for a urease test and. Patients
received omeprazole 20 mg, bismuth citrate 240 mg, tetracycline 500 mg, and furazolidone 200 mg, all twice daily for 7 days.
Therapeutic success was evaluated by endoscopy and biopsies 8 weeks after the end of treatment.
RESULTS: Sixty two patients were enrolled, and 58 completed the study. Under this protocol, H. pylori eradication was achieved
in 39/58 patients (67%). Mild adverse events were reported.
CONCLUSION: The short quadruple therapy course with furazolidone is well tolerated, inexpensive, and effective in retreatment
for H. pylori infection. It is a good option for developing countries.
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The importance of H. pylori as an etiological factor in
gastrointestinal ulcer is well established, and its eradication is
the main objective in the treatment of peptic ulcer disease.1-3
First-line eradication therapies for H. pylori associate
a proton-pump inhibitor with 2 types of antibiotics; this re-
sults in eradication rates of 80% to 90%. Consequently,
10% to 20% of patients will constitute therapeutic failure,4,5
the main reasons being low patient compliance with treat-
ment6 and bacterial resistance to the antimicrobial agents,7
especially to clarithromycin and metronidazole.8
The best retreatment regime has yet to be established.
Some international consensus statements recommend the
use of a quadruple therapy regime with a proton-pump in-
hibitor, bismuth subcitrate, metronidazole, and tetracycline
for 1 week, resulting in eradication rates of 57% to 95%,
with an average of 77%.4
A retreatment option that is more practical in Brazil in-
volves the use of furazolidone. In a country such as ours,
which has large populations with low socioeconomic levels
and high bacterial resistance to metronidazole,8 a simple, in-
expensive regime that is reasonably well tolerated by patients
is one that substitutes metronidazole with furazolidone.
This study aimed at establishing the efficacy and safety
of a 7-day therapeutic regimen used in the eradication of
H. pylori using omeprazole, bismuth subcitrate, tetracy-
cline, and furazolidone in a group of patients with peptic
ulcer disease who had been previously treated with other
therapeutic regimens without success.
METHODS
Patients were selected from the Outpatient Gastroenter-
ology Clinic of Hospital das Clinicas, Faculty of Medicine,
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University of São Paulo (HCFMUSP). The study was ap-
proved by the institutional Ethics Review Board for clini-
cal research, and all patients signed an informed written
consent form. Sixty-two patients with peptic ulcer who had
previously been treated unsuccessfully with one or more
eradication regimens for Helicobacter pylori (Table 1) were
included in the study. Bacterial persistence after treatment
was confirmed by positivity of the rapid urease test and his-
tological examination through a modified Giemsa staining
method. Gastric mucosa samples were obtained from the
antrum and corpus through upper digestive endoscopy.
Patients who were younger than 18 years of age were ex-
cluded, as were those who presented severe comorbidity, preg-
nant patients, infants, patients who had previously undergone
gastrectomy, patients with a known history of allergy to the
therapeutic regime drugs, and patients who had used nonster-
oidal antiinflammatory drugs (NSAIDs), antibiotic therapy, or
bismuth salts up to 4 weeks before study inclusion.
In an open, cohort study, the patients were invited to
use a therapeutic regime for 7 days that consisted of 20
mg omeprazole, 240 mg colloidal bismuth subcitrate, 500
mg tetracycline, and 200 mg furazolidone, taken twice a
day. Patients were warned not to ingest alcoholic beverages
and to avoid foods related to potential side effects deter-
mined for drugs similar to monoamine oxidase inhibitors.
They were also encouraged to take the full medication regu-
larly and were informed about the importance of an ad-
equate use of the medication for a successful treatment. No
other medication was allowed until the end of the treat-
ment, when patients were evaluated regarding compliance
by counting the remaining tablets. Adverse effects were re-
corded in a questionnaire, and each adverse effect was spe-
cifically investigated.
Treatment efficacy was determined by bacterial negativity
at the rapid urease test and histological examination of gas-
tric antrum and corpus mucosa samples taken during diges-
tive endoscopy performed 8 weeks after the end of treatment.
Statistical Analysis
Sample size calculation was determined for a descrip-
tive study of a dichotomous variable, considering the preva-
lence of peptic ulcer with resistant Helicobacter pylori in
2% of the general population and an expected eradication
efficacy of 70%. The eradication rates were calculated by
intention to treat and per protocol analysis.
All patients enrolled in the study were analyzed as in-
tention to treat (ITT). All the patients enrolled who took
more than 80% of the medication and those who returned
and agreed to undergo the control endoscopy were consid-
ered for the per protocol (PP) analysis. A confidence in-
terval of 95% was calculated for the eradication rate per-
centiles. The chi-square method with Pearson coefficient
was used for the comparison among the variables, eradi-
cation rate for previous treatment, gender, and age, with a
significance value of P < .05.
Statistical calculations were performed with the SPSS
statistics software, version 10.0 (SPSS Inc., USA).
RESULTS
Of the 62 patients enrolled in the study, a few had al-
ready undergone 3 or more previous treatments (Table 1).
There was no predominance regarding gender, and the av-
erage and median age of patients was 45 years. The preva-
lence of duodenal ulcer was high, and the prevalence of
smokers was similar to that in the Brazilian population9 (see
Table 2). Four patients were excluded from the analysis by
protocol, 2 for failing to undergo the control endoscopy, 1
for taking the medication inadequately, and 1 who inter-
rupted the treatment early due to the presence of adverse
effects (nausea and headaches).
The eradication rates were 67% (39/58) for the PP group
and 63% (39/62) for the ITT group (Table 3). There was
no difference in the eradication rates in relation to the
number of previous treatments the patient had undergone
(Table 4). Age and gender did not correlate with eradica-
tion rates either. Adverse effects were reported by 10% of
the patients, and these were usually considered to be slight.
Only 1 patient had to withdraw from treatment due to the
presence of nausea and headaches.
Table 3 - Eradication rates
 % 95% Confidence Interval
Per protocol 67% (39/58) 80% - 55%
Intention to treat 63% (39/62) 51% - 75%
Table1 - Unsuccessful previous treatments
Therapies Patients
1 37
2 20
3 or more 5
Total 62
Table 2 - Clinical data
Patients 62
Age (years) mean 45
Median 45
Interval 18 - 74
Women 50%
Duodenal ulcer 71%
Tobacco users 22%
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DISCUSSION
In recent years, an increase in the number of patients
who present therapeutic failure with H. pylori eradication
regimens has been observed. Antimicrobial resistance has
been described as the main reason for this failure. Thus,
several alternative therapeutic regimens have been tested
with the objective of attaining an effective retreatment of
such patients.
In our country, it is costly and unfeasible to verify anti-
microbial sensitivity in all patients who need retreatment, even
for large centers, and few of them perform the bacterial sen-
sitivity test. Hence, retreatment regimens are not based on the
antibiogram of the resistant Helicobacter, but rather on the
knowledge of the previously used antibiotic therapy.
In this study, many patients were referred from other
medical centers and had previously been treated with dif-
ferent drug regimens, with clarithromycin and metronida-
zole being the most frequently used antibiotics.
It is known that clarithromycin and metronidazole re-
sistance is common in all parts of the world and that it has
been increasing.10–15 In developing countries, where the use
of metronidazole is very common in the treatment of para-
sitic infestations, 40% to 70% of the strains are resistant
to this drug.12,16,17
Furazolidone is a synthetic nitrofuran derivative with
bactericidal or bacteriostatic activity when used against
Gram-positive and Gram-negative bacteria, and it is well
absorbed in the intestine with no tissue accumulation.18–20
It has been used in China for more than 20 years in the
treatment of peptic ulcer as the single therapeutic agent,
with healing rates comparable to those obtained with
cimetidine and displaying lower recidivation rates.21,22 It is
currently known that the good results are mostly due to its
anti-H. pylori activity.23,24
Furazolidone-resistant strains25,26 have not been de-
scribed to date, which makes its use an alternative in the
retreatment of peptic ulcer disease caused by H. pylori.
One of the great impediments regarding the use of fura-
zolidone is its association with significant adverse effects,
reported mainly in studies carried out in Europe, where it is
no longer considered a drug of choice for retreatment regi-
mens.27,28 Our study, however, produced different results from
those found in the literature, since only 1 patient had to in-
terrupt the treatment due to the presence of side effects.
The eradication rates (67% PP and 63% ITT) were a
little lower than those reported in other studies based on
this therapeutic regimen.29 It is possible that the use of only
1 g/day of tetracycline and 400 mg/day of furazolidone may
explain the results obtained. With the aim of achieving a
higher compliance rate by patients with the quadruple
therapeutic regime, it was administered for only 7 days,
although several consensus statements suggest a 14-day
duration.30,31 It is possible that a more prolonged treatment
might result in better eradication rates.
In conclusion, our study showed that the association of
furazolidone with a proton-pump inhibitor plus tetracycline
and colloidal bismuth subcitrate could be a valuable alter-
native for patients who need retreatment for H. pylori eradi-
cation. It is an effective, affordable treatment that allows
good compliance and produces low adverse effect rates.
RESUMO
Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti
RC. Esquema quádruplo com furazolidona para retrata-
mento do Helicobacter Pylori, em pacientes ulcerosos.
Clinics. 60(6):485-8.
OBJETIVO: Muitos dos esquemas atualmente usados na
erradicação do Helicobacter pylori não conseguem curar
a infecção, pela resistência bacteriana ou pela baixa ade-
são do paciente. Esta condição manterá os riscos de de-
senvolvimento das potenciais complicações graves da in-
fecção. Este estudo procurou determinar a eficácia e segu-
rança de um esquema quádruplo que associou a furazoli-
dona para o retratamento da infecção pelo H. pylori.
MÉTODOS: Pacientes que não alcançaram erradicação em
um ou mais tratamentos foram submetidos à endoscopia
digestiva alta e dois fragmentos do antro e do corpo foram
retirados para exame histológico e de urease. Receberam
então 20mg de omeprazol, 240mg de sub-citrato de
bismuto, 500mg de tetraciclina e 200mg de furazolidona
duas vezes ao dia por 7 dias. O sucesso terapêutico foi de-
terminado pela negativação de nova biópsia endoscópica,
após 8 semanas do tratamento.
RESULTADOS: Sessenta e dois pacientes foram incluí-
dos, cinqüenta e oito completaram o estudo. Por protoco-
lo, 67% (39/58) dos pacientes conseguiram a erradicação
da bactéria. Efeitos adversos leves foram relatados.
Table 4 - Eradication rates and previous treatments
Treatments Rates
1 65% (23/58)
2 74% (14/58)
3 or more 60% (3/5)
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CONCLUSÃO: O tratamento de curto prazo, em esque-
ma quádruplo com a furazolidona , é bem tolerado, barato
e eficaz no re-tratamento do H. pylori. Uma boa opção de
re-tratamento para países em desenvolvimento.
PALAVRAS-CHAVE: Úlcera péptica. Tratamento.
Helicobacter pylori. Erradicação. Helicobacter pylori re-
sistente. Terapia quádrupla. Furazolidona.
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